Takeda’s answer to Sanofi’s controversial dengue vaccine is here. The Japanese drugmaker, which is hoping to avert the challenges faced by its French rival to develop a product for the mosquito-borne disease, broke out the numbers from the first tranche of its pivotal trial on Wednesday.